कंपनी का अवलोकन
Bluejay Diagnostics, Inc. operates primarily within the healthcare sector, specifically functioning as a medical diagnostics company focused on medical devices. The firm offers a proprietary Symphony technology platform which includes an analyzer paired with single-use protein detection cartridges designed to measure key diagnostic biomarkers found in blood samples. This operational model positions the company to serve clinical environments requiring rapid and precise biomarker analysis for patient diagnosis and monitoring. In terms of scale, the entity currently maintains a market capitalization of $1.87M while employing a workforce of 6 individuals. The annual revenue figure is not disclosed in available financial records, indicating that the company likely operates at a micro-cap stage with minimal or unreported sales volume. The combination of a sub-$2M market cap and an absence of reported revenue suggests that the company is in an early development or pre-revenue phase, where valuation is driven more by potential technology adoption than by current cash flow generation.
वित्तीय स्वास्थ्य
The financial statements for the trailing twelve months indicate a net income of $-6,848,483 and an EBITDA of $-6,842,535, while the revenue remains unreported. The significant gap between the reported net income loss and the EBITDA figure reveals a substantial impact from non-operating expenses or interest costs, as EBITDA excludes these items to focus on core operational profitability. Free cash flow stands at $-3,706,221, which signifies that the company is currently burning cash faster than it generates through operations, thereby limiting its immediate financial flexibility for expansion or debt repayment without external financing. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved profitable operations or that reported sales do not cover the cost of goods sold in a manner that generates a positive percentage return. On the balance sheet, the company holds $5.16M in cash against a total debt obligation of $129,558, resulting in a debt-to-equity ratio of 2.17. Although the cash position significantly exceeds total debt, the elevated debt-to-equity ratio suggests a leveraged capital structure relative to shareholder equity, which can amplify losses if earnings do not improve. The current ratio is 4.88, a metric that indicates robust short-term liquidity and the ability to cover current liabilities with current assets well over four times. Return on Equity is -117.0% and Return on Assets is -62.8%, figures that reveal management is currently destroying shareholder value and utilizing assets inefficiently in the context of profitability.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is not available due to negative earnings, whereas the forward P/E is listed as -5.66, implying that the market expects the company to remain unprofitable in the near term or that valuation models are using alternative assumptions for future earnings growth. The price-to-book ratio is 0.18, suggesting that the stock is trading at a significant discount to its book value, which may reflect market skepticism regarding the recoverability of assets or the ability to generate returns on that capital. The price-to-sales ratio is not available, and the EV/EBITDA multiple is 0.48, a metric that often appears in negative scenarios for high-growth, pre-profitability biotech or medtech firms where traditional multiples are less relevant. The stock has exhibited significant volatility over the past year, with a 52-week high of $16.68 and a 52-week low of $1.65. Without a specific current share price provided in the facts, the range indicates a massive swing in investor sentiment, with the asset capable of trading anywhere within this wide band depending on market conditions and clinical data releases. The beta value is 0.67, which indicates that the stock's price volatility is lower than the broader market average, suggesting it may move less drastically than the overall market index during periods of systemic stress.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both not available, preventing a direct comparison of growth rates between top-line sales and bottom-line profits. The absence of these growth metrics suggests that the company is not yet in a mature growth phase where consistent year-over-year expansion is measurable or standardized in reporting. Regarding income distribution, the company does not pay dividends as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company does not return capital to shareholders via dividends but instead retains all earnings or available cash reserves for reinvestment into research, development, or operational scaling. The overall growth and income profile for Bluejay Diagnostics, Inc. is characterized by a lack of historical revenue data, negative earnings growth due to losses, and a complete absence of dividend income, focusing entirely on capital appreciation potential through stock price movement rather than yield or consistent earnings expansion.